drugset
drugset / Trial / NCT03035006

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

NCT03035006 ↗

Phase 1/2 Terminated 1 enrolled Taiwan Liposome Company
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.

Timeline

Start
2017-04-14
Primary completion
2018-10-31
Completion
2018-10-31

Outcome

Outcome not reported

Stopped: “Current study design couldn't support futher development on this indication.”

Drugs

EvaluationDrugModalityDoseRoute
Subject TLC388 Small molecule — Intravenous

Indications

hepatocellular carcinoma portal vein thrombosis